Atsena prioritizes retinal gene therapy pipeline, trims staff as existing investors refuel the biotech
Atsena Therapeutics has reduced its staff, is looking for a partner and has reeled in more cash from existing investors, the gene therapy biotech told Endpoints News.
The North Carolina startup anticipates 12-month results from its first Phase I/II clinical trial by year’s end and began a separate Phase I/II study of its second gene therapy in August, but has recently laid off employees to conserve cash, which includes a recent insider-led Series B, the company said, with about $24.5 million of $32 million raised so far, per an SEC filing. CEO Patrick Ritschel declined to disclose the size of the workforce reduction.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.